1. Pink Sheet

The Story So Far: The UK’s New Licensing And Access Pathway

More Than 35 'Innovation Passports' Have Been Issued

 
• By Ian Schofield

As the UK’s new pathway for innovative drugs approaches the end of its first year of operation, representatives of the national regulatory agency and England’s HTA body assess progress so far, including the greater role assigned to patients in the system.

Gene therapies are among products that could benefit from the UK's new licensing and access pathway • Source: Alamy

The Innovative Licensing and Access Pathway (ILAP) launched in the UK in January this year is proving popular, with 67 applications received so far for an innovation passport, a designation that allows innovative medicines access to the new pathway.

ILAP is intended to offer a more integrated approach to drug development and access by involving several bodies including the regulatory agency, the MHRA, the UK health

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Mayne’s Nextstellis Promo Wrong To Suggest Better Safety Than Other Contraceptives, FDA Says

 
• By Sue Sutter

A professional slide deck for the drospirenone/estetrol oral contraceptive inappropriately suggests it is safer than other estrogen-containing products and understates risks, Office of Prescription Drug Promotion said in the first “untitled” letter issued since reductions-in-force.

US HHS Deputy Nominee Talks AI, Not FDA, In Confirmation Hearing

 
• By Ramsey Baghdadi

Silicon Valley investor Jim O’Neill’s Senate confirmation hearings showcased the unique background of someone with government and tech experience and avoided discussions of his past statements about lowering the bar for regulatory approval.

US FDA Waiting On Guidance Agenda Future As HHS Seeks Regulation Cuts

 
• By Derrick Gingery

The FDA continues to wait for a decision on whether its priority guidances will be published as HHS asks the public for potential regulation cuts to fulfill President Trump’s executive order.